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Abstract
Toxoplasma gondii infection generally causes flu-like symptoms in healthy individu-
als; however, immunosuppression of the infected individual causes reactivation of the 
pathogen to its active form and relapse of the toxoplasmosis. Today it is known that 
toxoplasmosis triggers psychiatric disorders such as schizophrenia as well as behavioral 
changes such as suicide attempts. Although dermatological manifestations are very rare, 
the dermatological lesions are not unique. In addition, previous toxoplasma infection 
also causes congenital infections because of placental infection and causes birth defects 
and spontaneous abortion. T. gondii strains are mainly divided into three main clonal 
lineages, yet higher recombination rate causes unusual population structure and hetero-
geneous distribution of the pathogen. Both genetic variations, of the pathogen and the 
patients, are important for virulence property and success of the therapies. The scientist 
focuses on the genetic variations of the pathogens and individuals to achieve effective 
treatment and developed tailor-made medicines. Thus, understanding the molecular 
basis of the disease and the link of molecular mechanism with host immunity is impor-
tant to fully know the disease and related disorders. In this chapter, we would like to 
evaluate the current knowledge on genetic, molecular characteristics of toxoplasmosis in 
view of public health genomics.
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1. Introduction
Toxoplasma gondii is a life-long infectious protozoan parasite and thus understanding the 
immunological and molecular pathways during toxoplasmosis is important for effective 
treatment and vaccine development. T. gondii infection and related neurological, behavior, 
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 dermatological, and ocular manifestations are an important area of current research. In addi-
tion, the molecular life cycle of the pathogen, immunologic, and genetic changes during the 
infection is also important to diagnose and improve new treatment strategies. The other 
important research area related to toxoplasmosis is development of safe and efficient diag-
nostic assays for early detection of pathogens during pregnancy period.
It is thought that T. gondii has a role in the etiology of schizophrenia and that parasites have 
special genes that can be inherited. However, there are some limiting factors. In schizophre-
nia, it is difficult to show the cause of toxoplasmosis in brain tissue. T. gondii can also be found 
in brain tissue in immunocompetent individuals. Moreover, not all of the T. gondii-infected 
individuals develop schizophrenia. Increased risk of exposure to T. gondii has been shown in 
schizophrenic patients, but the exposure relationship is often studied by case-control studies. 
Despite the cohort-type studies that show the best relationship between the etiologic agent 
and the disease, researchers prefer to work in case-control type because of the latent course of 
the disease, not being a common disease in society, and difficulties in follow-up. It should be 
kept in mind that genetic factors as well as environmental exposures may increase the risk of 
this disease and that the presence of the agent before disease development may better explain 
the causal relationship.
We need a perspective of public health genomics to better understand the relationship between 
schizophrenia and toxoplasma, which is one of the most frequently used topics in recent years, 
and also in order to better understand the public health effects of parasites. The clear under-
standing of the histological, biochemical, and genetic characteristics of parasites can also 
explain the mechanisms of disease development. For this purpose, in this chapter, genotypic 
features of Toxoplasma gondii, other molecular changes, and mechanisms of schizophrenia 
development are discussed and suggestions are given in terms of public health.
2. Molecular basis of toxoplasmosis
The first line of defense against T. gondii compose of dendritic cells (DCs), monocytes, and 
macrophages, and Toxoplasma induces toxoplasmosis-specific CD4+ and CD8+ T cells, which 
are the secondary defense systems. The ligands expressed by T. gondii are recognized by toll-
like receptors (TLR) [1–3] and stimulate IL-12 production via MyD88 signaling [4, 5]. GPI-
anchored proteins of T. gondi is important for both adhesion to host and regulate host immune 
system via TLR2 and TLR4 on macrophage surface [2, 3] aside profilin that secreted from T. 
gondii binds to TLR11 on dendritic cells [5]. Pro-inflammatory IL-12 secretion triggers IFN-γ 
production by NK cells; thereafter, CD4+ and CD8+ T cells join to release IFN-γ [6], and then 
IFN-γ binds to a receptor tyrosine kinase (IFN-γ-R) and activates the JAK/STAT1 cascade by 
JAKs phosphorylation (Figure 1).
Activation of JAKs phosphorylates the tyrosine residue of STAT1 and cause dimerization of the 
molecule hence translocate the nucleus [7] then binds to IFN-γ-responsive gamma-activated 
site (GAS) consensus sequence and initiate the transcription of IFNγ-inducible genes Irf-1 and 
Lrg47 [7, 8]. In addition to T-cell mediated immunity, STAT1 induces nitric oxide (NO) and 
reactive oxygen species (ROS) production in monocytes and macrophages [9]. Lüder et al. [10] 
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have reported the toxoplasma IFN-gamma-induced gene expression via STAT1 pathway. In 
addition, STAT4-dependent IFN-γ has been reported in dendritic cells and macrophages [11]. 
Many reports have been shown the T. gondii success of toxoplasma’s immune evasion strate-
gies [10, 12, 13]. The molecular basis of parasite-host interaction is important in understand-
ing the disease mechanism and developed successful treatment strategy (Figure 2).
Figure 1. Immune response to Toxoplasma gondii infection in humans.
Figure 2. JAK-STAT pathway is important to induce toxoplasma-related response genes. INF-γ binds to its receptor 
(A) and activates the tyrosine kinase activity of receptor (B) and hence the phosphorylate SH2 domain of the STAT 
(C). Phosphorylation of the STAT triggers dimerization of the molecule (D) and conformational changes cause nuclear 
localization of the STAT which then binds to the nuclear response sequence on promoter region (E) to induce expression 
of target genes.
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3. Genetic variation of Toxoplasma gondii
The complexity of an organism is directly related to its genome, and the variation on para-
site genome is crucial for their success during evolution. In addition to natural selection, the 
pharmacy industry also forces parasites for evaluation; thus, genomic diversity also means 
successful pathogenicity.
Toxoplasma gondii consists of three main clonal lineages (types I, II, and III) among North 
America and Europe [14], and type II is the major strain that causes human infections in 
North America [14] and Europe [15, 16]. Early studies that performed multilocus enzyme 
electrophoresis (MLE) had limitations to show biological and epidemiological diversity [17].
Nowadays, high throughput technologies allow the scientist to understand the genetic diver-
sity of T. gondii. In contrast, genetic analyses that were performed by multilocus markers 
have been shown that isolated samples from South America were highly diverse from each 
other and also from European and North American strains [15–18] due to a higher recombina-
tion rate [19]. The recent researchers have been shown that T. gondii has unusual population 
structure with different growth rates [20], frequency of differentiation, motility [21] virulence, 
persistence, and migration capacity [15, 21–23]. Recent developments in molecular tools 
allow enhancing their success to identify the genetic diversity of the parasite [24, 25]. Su et al. 
[25, 26] have analyzed the nuclear and plastid genome of 950 isolates from all over word and 
reported six major clades dividing 15 haplotypes with 138 unique genotypes. Ning et al. [22] 
have reported that toxoplasma dense granule protein 20 (GRA20) may be useful for intra-
specific phylogenetic analyses. Wang et al. [27] have reported that rhoptry protein 47 may be 
used as a genetic marker for a phylogenetic relationship. In contrast, genes with low sequence 
variation such as superoxide dismutase (SOD) are not useful for variation analyses [28, 29].
4. Importance of human genetic variation for toxoplasmosis infection
Nowadays, researches are focused on the personalized medicine by using genetic variations of 
the patients to develop tailor-made therapeutics for appropriate and optimal therapies. The most 
important part to develop tailor-made therapeutics understands the relation between molecular 
basis of the disease and phenotypic screening. In addition, genomic variation is also important 
to understand personal immune response to a specific disease or therapeutic efficiency.
Toll-like receptor (TLR) is a single-pass transmembrane, non-catalytic receptor family, which 
is crucial for an early innate immune response during evolution. TLR expression differs in 
the stage of pregnancy, and a different subtype of TLR is activated or deactivated in placental 
tissues during pregnancy period [30, 31]. Nishimura and Naito have shown that TLR3 expres-
sion was the highest in placenta [32]. TLR is linked to infertility [33], pregnancy disorders, and 
placental dysfunction [34]. In toxoplasmosis TLR2, TLR4, TLR9, and TLR11 have been found 
important for recognition of ligands expressed by T. gondii [1, 35–37]. Andrade et al. [38] have 
demonstrated TLR7 and TLR9 sense T. gondii-associated nucleic acids (DNA or RNA) while 
TLR11 and TLR12 sense Toxoplasma profiling. Thus, understanding genomic variations in 
TLR is important to highlight immune defense against T. gondii [30, 39, 40]. NOD-like  receptor 
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(NLR) families are important for immediate responses against structures that are present in 
T. gondii like TLR receptors. Dutra et al. [41] have reported that NOD2 gene polymorphism 
(rs3135499) increases the ocular toxoplasmosis by its effects on IL-17A production. Witola 
et al. [42] have reported that NALP1, a member of the NLR family of proteins, is crucial 
for immune responses to T. gondii infection and pathogenesis. Variation in immunity-related 
genes is also associated with toxoplasmosis. Shimokawa et al. [43] have shown that HLA-
DQA1 and DQB1 alleles are increasing the risk of congenital toxoplasmosis. In conclusion, 
human genomic variation influences the defense against T. gondii as well as its manifestations 
of congenital infection and ocular toxoplasmosis.
5. Immunohistochemistry of toxoplasmosis
Toxoplasmosis can cause severe fetal conditions during pregnancy, and this fetal influence 
is related to the trimester of pregnancy. Toxoplasma gondii infection in the first trimester of 
pregnancy (4th week) can cause serious neurological and ophthalmological damage as well 
as spontaneous termination of pregnancy [44]. Infection of the nervous system leads to cen-
tral nervous system injuries including hydrocephalus, microcephaly, motor mental retarda-
tion, and intracranial calcifications. Microphthalmia can also be observed in the first trimester. 
Toxoplasma gondii infection in the second and third trimester may result in chorioretinitis, 
visual defects, and mild neurological sequelae [45]. Dermal symptoms of Toxoplasma gondii in 
fetus are nonspecific and differs in each trimester.
Histopathological report attracted attention to especially parasitic infiltration and also inflam-
matory cell infiltration in affected tissue during toxoplasmosis. Immunosuppressive patients 
because of reduced inflamatory response due to immunne suppressive agents. Thus, immu-
nohistochemically staining with appropriate antibodies will be helpful in these cases [46, 47]. 
Pathologic changes especially visible in skin lesions are pseudoepitheliomatous hyperpla-
sia and perivascular lymphohistiocytic infiltration. Parasites can be seen in macrophages by 
hematoxylin eosin staining or as its single parasitic form by basophilic staining. Bradyzoites 
form that contains tissue cysts can be visualized by hematoxylin-eosin, Giemsa, Mallory, 
Biondi, and PAS reagent [48]. Parasites can also be visualized immunohistochemically by 
marking them with antigen-specific antigens inside the host tissue [49]. Tachyzoites are able 
to be visualized by light microscopy from samples taken from infected tissues [48, 50]. In 
addition to light microscopy, immunofluorescence methods can be used to detect parasites 
and to show them microscopically in samples taken from infected tissues with parasites [50].
6. Toxoplasmosis and psychiatric patients
6.1. Behavioral changes and toxoplasmosis
Kozar has shown the relationship between toxoplasma infection and psychiatric disorders 
for the first time [51] T. gondii, present in one-third of the world’s population, may be associ-
ated with an increase in suicide rate [52]. T. gondii, a neurotrophic parasite, plays a role in the 
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 development of schizophrenia and causes behavioral changes, suicide attempts, and neuro-
pathological degenerations in the brain tissue [53–56, 74]. T. gondii has a role in the develop-
ment of behavioral disorders via changes in neuroimmunomodulation and neurotransmission, 
yet pathophysiological mechanisms are not fully understood by scientists [57, 58].
6.2. Schizophrenia and toxoplasmosis.
Several studies and later metaanalyses have been reported the association between Toxoplasma 
gondii infection with schizophrenia [55, 59, 60]. It has been shown that T. gondii-infected indi-
viduals increase the risk of schizophrenia when compared to healthy individuals, yet these 
relationships were only examined by case-control studies. Epidemiologically, the best way to 
show the relationship between the agent and the disease is to work in cohort type. In contrast, 
the researchers prefer to work in case-control type studies because of the latent course of the 
disease, the difficulties encountered in the follow-up, and the life cycle pathogen and rare 
nature of disease. It should be kept in mind that genetic factors as well as environmental expo-
sures may increase the risk of this disease. Previous toxoplasma infection before neurological 
disease development may better explain the causal relationship.
Schizophrenia susceptibility genes are associated with life cycle of T. gondii [61]. The factors 
that play a role in the etiology of the disease time of infection, genetic variation of T. gondii, 
and strain of the parasite [60]. In addition to the genetic characteristics of infected individuals, 
immigration or being the offspring of immigrants is also related with schizophrenia among T. 
gondii-infected humans [62].
T. gondii and schizophrenia relations have been linked in many studies [63], and generally it’s 
accepted that T. gondii triggers psychiatric disorders via affecting neurotransmitter secretion 
[54]. It is known that the T. gondii genome contains two aromatic amino acid hydroxylases 
that can directly affect dopamine and/or serotonin biosynthesis [64]. It is unclear how T. gondii 
increased dopamine levels; however, the dopamine is released during inflammation due to 
the increase of cytokines such as interleukin-2 (IL-2) [65, 66]. Hence, dopamine imbalance in 
the mesolimbic and mesocortical regions of the brain may play a role in the development of 
schizophrenia [67].
T. gondii modulates host gene expression by secretion of effector molecules [68] or cause 
post-translational modification such as acetylation of protein residues in neurons and glial 
cells [69]. The success of the pathogen is its virulence ability to cross biological barriers such 
as the blood brain barrier [70]. In a study, Du et al. [68] demonstrated that T. gondii termi-
nates the NF-κB pathway by its rhoptry protein that causes p65 ubiquitination for protea-
somal degradation. In a study, it has been shown that T. gondii changes lysine acetylation in 
astrocytes [69].
TOXO-specific IgG and IgM antibody levels are elevated in schizophrenia [71–75]. In a 
study in which other demographic variables might affect age, race, sex, and mortality, it was 
found that the risk of death in serologically positive individuals was five times higher than 
Toxoplasma gondii seronegative ones [75]. Toxo-specific IgG antibody level was found four 
times higher in patients with schizophrenia than in individuals without [76].
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Torrey has shown that Toxoplasma seroprevalence in individuals with schizophrenia is 2.73 times 
higher than the control population [60]. In a study, Emelia et al. [77] have shown significant sero-
intensity rates of anti-T. gondii IgG antibody in schizophrenic patients when compared to psychi-
atrically healthy volunteers. Tamer et al. [78] have shown that IgG T. gondii antibodies were higher 
in patients with schizophrenia when compared with controls, and in contrast, Karabulut et al. 
[79] have reported that there is no association between T. gondii IgG positivity and schizophrenia.
7. Toxoplasmosis and dermatological disease
Dermatological manifestations are rare and diagnosis of lesion is difficult. Skin lesions in con-
genital infections are usually exfoliative lesions and hemorrhagic and necrotic papules (small 
papules in the shape of ‘blueberry muffins’). These lesions tend to hold the body. But it can 
be seen in the entire body, except in the palmoplantar region and face. The skin findings of 
toxoplasmosis are very varied: the dermatological lesions are reported as roseola, erythema 
multiforme [80], papular urticaria [80, 84], urticarial, hemorrhagic eruptions, formation of 
nodules and bullae [81, 82] on palms, soles, hands, legs, trunk, face and chest [83, 84]. Jeffrey 
and Pollock have shown a 12-year-old boy patient with dermatomyositis and polymyositis 
and offered to use sulfadiazine, pyrimethamine, and folinic acid for treatment [85]. Fong et al. 
[81] have reported a 49-year-old HIV-positive Chinese male with hard and painful nodular 
lesions. Ivanova et al. [86] described a case of 46-year-old male patient with acute toxoplasma 
lymphadenitis, similar to malignant cervical lymphadenopathy. In another study performed 
by Marina et al. [87], scientists reported a case of a 43-year-old immunocompetent man who 
has several erythematous papules and nodules on the body and extremities.
Histopathologic features are common for both acquired and congenital forms. Lymphocytes, 
macrophages, plasma cells, and superficial and deep perivascular infiltration, which is com-
posed of eosinophils, are seen in the dermis. Tissue forms of T. gondii may not always be seen 
in specimens of biopsy taken from the lesion.
It is important that congenital toxoplasmosis is distinguished from the TORCH group of 
infectious diseases. Acquired toxoplasmosis may be confused with inflammatory diseases 
such as viral exanthema, meningococcemia, syphilis, urticarial vasculitis, and erythema mul-
tiforme associated with herpes simplex and autoimmune collagen tissue diseases. If active 
acute infection occurs in organs such as the skin or the eye, or congenital infection occurs, 
or immunosuppressed patients need treatment, the most effective treatment method is pyri-
methamine (from 25 to 50 mg per day followed by 100 mg loading) and sulfadiazine (2–4 
mg per day oral, divided into four doses). Patients allergic to sulfonamides may be given 
clindamycin (300 mg, four times a day).
8. Toxoplasmosis and pregnancy
T. gondii is an important, warm-blooded pathogen that causes congenital infection during 
pregnancy which results in cardiovascular, cerebral, and ocular damage in newborns by 
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transplacental infection [87, 88]; T. gondii infection also causes birth defects and spontaneous 
abortion [89–92].
Determination of T. gondii infection is crucial during pregnancy to decrease congenital 
toxoplasmosis [91] and thus companies try to develop new commercial tests. The serologic 
screening of IgM, IgA, and IgG is important to determine current or past infections of the 
pregnant women [88, 93]. In addition to serological methods, ELISA IgG avidity is also 
found safe, efficient, and easy to determine T. gondii infection in the first trimester of preg-
nancy in routine diagnostic treatment [94, 95]. PCR is an effective diagnostic tool to deter-
mine the pathogen in a tiny amount of sample with high specificity [96–98]. The scientist’s 
efforts to develop efficient and safe methods to alternates of ELISA, IFA, or modified agglu-
tination test (MAT [88] or to develop these commercial ones to eliminates limitations of pre-
vious ones are ongoing [99, 104]. Armengol et al. [100] have compared different commercial 
assays which use anti-Toxoplasma IgG seroconversion in pregnant women and efficiency 
of the assays differs.
Pomares et al. [101] have developed new multiplexed T. gondii IgG and IgM tests which allow 
determining the pathogen in ~1 microliter of the serum sample. Mahmoudi et al. [102] have 
developed ELISA-based interferon-gamma release assay for the early detection of the patho-
gen. Mohammadpour et al. [103] have been reported that tachyzoites form of T. gondii able 
to detect via its soluble crude antigens by ELISA. Robert-Gangneux et al. [104] have been 
developed efficient toxoplasmosis assay which able to diagnose from non-cell-rich or non-
hemoglobin-rich samples by real time PCR.
The development of diagnostic tests is particularly important in addressing the difficulties 
encountered during routine follow-ups by the population. Common guidelines are needed 
to guide both patients and clinicians in the subsequent processes, especially when toxoplas-
mosis is diagnosed in pregnancies. Sensitive tests to be developed for definite diagnosis are 
very important because there are problems related to diagnosis in pregnancy. T. gondii scans 
should be done serologically in cats and dogs at the same time. There is a need for regional 
studies on toxoplasmosis, especially in developing countries because socio-cultural features 
play a role in the development of the disease. As in many countries, studies in Turkey are 
continuing. There are studies on seroprevalence of toxoplasmosis and schizophrenia reported 
from the University and State Hospital in our research area Canakkale [105–108].
9. Conclusion
Attention should be paid to veterinary basic health services in combating and protecting 
zoonoses, which are thought to be an important risk factor in schizophrenia etiology such 
as T. gondii. While the risk of being infected with T. gondii by individuals living in urban 
centers increases risky behaviors such as cat feeding, cleaning of cat external feces, and con-
tact with street cats; these risks are the factors such as contamination of animal products, 
consumption of raw meat and meat products, general hygiene conditions and inadequate 
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water hygiene in the people living in rural areas and living with agriculture and animal 
husbandry. Therefore, it is more effective and useful to plan the health trainings and surveys 
that are to be carried out, considering the socio-demographic and environmental character-
istics of these target groups.
Data obtained in screening studies should be recorded with geographic information sys-
tems, and risky areas should be identified and individuals at risk (primarily pregnant 
women, children, people with psychiatric health problems) living in these areas should be 
regularly monitored. Trainings should be given on healthy lifestyle behaviors, such as per-
sonal and environmental hygiene. In clinical practice, in order to prevent T. gondii from 
being missed, in-service trainings should be made to raise awareness and responsibility for 
health personnel.
In order to overcome the question marks in the schizophrenia mechanism, a gene pool can 
be created on serum samples obtained from regional and national studies, and the present 
and changing immunogenetic structure of parasite can be monitored. This important point of 
public health and genetics is that infectious agents are monitored in a large pool of genes to 
monitor the changes they show and to help them analyze the distribution of health problems 
caused by infectious agents in their populations and risk factors. We also believe that the 
molecular monitoring of parasites such as toxoplasma will help to improve the early diag-
nosis and treatment of parasitic infections, which are the most important of public health 
problems, and the prevention and control of these infections.
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